3-bromoquinoline

Endpoint summary

Key value for chemical safety assessment

Genetic toxicity in vitro

Description of key information

Gene mutation toxicity study was performed by Asim Kumar Debnath et al (Mutation Research, 1992) to determine the mutagenic nature of 3-Bromoquinoline (5332-24-1) using Salmonella typhimurium strains. 3-Bromoquinoline was assessed for its possible mutagenic potential. For this purpose AMES test was performed  in Salmonella typhimurium strains TA 98 and TA 100. The test material was exposed at the concentration of 0, 6.7,10,33,67,100,333,667 and 1000 µg/plate in the presence and absence of S9. No mutagenic effects were observed. Only the data on TA100 with metabolic activation are reported here (Table) as the test substances tested on TA98 with and without S9 activation and on TA100without S9 activation were inactive. Therefore 3-Bromoquinoline was considered to be non mutagenic in presence and absence of S9.Hence the substance cannot be classified as gene mutant in vitro.

Link to relevant study records

Reference

Endpoint:

in vitro gene mutation study in bacteria

Type of information:

experimental study

Adequacy of study:

weight of evidence

Reliability:

2 (reliable with restrictions)

Rationale for reliability incl. deficiencies:

study well documented, meets generally accepted scientific principles, acceptable for assessment

Justification for type of information:

Data is from publication.

Qualifier:

according to guideline

Guideline:

other: As mention below

Principles of method if other than guideline:

To evaluate the mutagenic potential of 3-Bromoquinoline in Salmonella typhimurium strains TA 98 and TA 100 by Ames test.

GLP compliance:

not specified

Type of assay:

bacterial reverse mutation assay

Specific details on test material used for the study:

Details on test material
- Name of test material (as cited in study report):
- Molecular formula: C9H6BrN
- Molecular weight:
- Substance type: 208.057g/mol
- Physical state: Organic
Purity;> 99% using HPLC.

Target gene:

Histidine

Species / strain / cell type:

S. typhimurium, other: TA 98 and TA 100

Details on mammalian cell type (if applicable):

Not applicable

Additional strain / cell type characteristics:

not specified

Cytokinesis block (if used):

not specified

Metabolic activation:

with and without

Metabolic activation system:

S9 microsomal fraction

Test concentrations with justification for top dose:

0,6.7,10,33,67,100,333,667 and 1000 µg/plate

Vehicle / solvent:

Vehicle
- Vehicle(s)/solvent(s) used: DMSO ,50µl

Untreated negative controls:

not specified

Negative solvent / vehicle controls:

yes

Remarks:

DMSO

True negative controls:

not specified

Positive controls:

yes

Positive control substance:

other: (+ S9) 2-aminoanthracene ; TA98 and TA100 (-S9) 2-nitrofluorene ; TA98 (-S9)sodium azide;TA 100

Details on test system and experimental conditions:

Details on test system and conditions
METHOD OF APPLICATION: in medium; in agar (plate incorporation
DURATION
- Preincubation period: 20 min
- Exposure duration: 48 hour

NUMBER OF REPLICATIONS: Triplicates

Other: Plates not counted immediately were stored at 4°C. An automated colony counter was used for counting except when there was interference due to precipitation of test article and then manual counting was used.

Rationale for test conditions:

Not specified

Evaluation criteria:

The revertants/ nmole were calculated by converting dose in Kg to nmole and taking the slope of the linear regression line of the dose-response curve. The logarithms of the slopes (revertants/ nmole) were used as activity parameters

Statistics:

Mean± Standard deviation was observed.

Species / strain:

S. typhimurium, other: TA 98 and TA 100

Metabolic activation:

with and without

Genotoxicity:

negative

Cytotoxicity / choice of top concentrations:

not specified

Vehicle controls validity:

valid

Untreated negative controls validity:

not specified

Positive controls validity:

valid

Remarks on result:

other: No mutagenic effect were observed.

Sr no		Dose	Revertants/plate (mean ±standard Deviation100 (+ S9)
1	Control
	DMSO	50µl	153± 3
2	Test substance name	(µg/plate)
	3 -Bromoquinoline
		6.7	152± 17
		10	160±9
		33	125±7
		67	157± 6
		100	121±15
		333	133±16
		667	34±41
		1000	0±0

 

Conclusions:

3-Bromoquinoline (5332-24-1) was evaluated for its mutagenic potential in Salmonella typhimurium strains TA 98 and TA 100 by Ames test. The test result was considered to be negative with and without S9.

Executive summary:

3-Bromoquinoline was assessed for its possible mutagenic potential. For this purpose AMES test was performed  in Salmonella typhimurium strains TA 98 and TA 100. The test material was exposed at the concentration of 0, 6.7,10,33,67,100,333,667 and 1000 µg/plate in the presence and absence of S9. No mutagenic effects were observed. Only the data on TA100 with metabolic activation are reported here (Table) as the test substances tested on TA98 with and without S9 activation and on TA100without S9 activation were inactive. Therefore 3-Bromoquinoline was considered to be non mutagenic in presence and absence of S9.Hence the substance cannot be classified as gene mutant in vitro.

Endpoint conclusion

Endpoint conclusion:

no adverse effect observed (negative)

Genetic toxicity in vivo

Endpoint conclusion

Endpoint conclusion:

no study available

Additional information

Genotoxicity In-vitro

Various publications were reviewed to determine the mutagenic nature of 3-Bromoquinoline (5332-24-1). The studies are as mentioned below:

Gene mutation toxicity study was performed by Asim Kumar Debnath et al (Mutation Research, 1992) to determine the mutagenic nature of 3-Bromoquinoline (5332-24-1) using Salmonella typhimurium strains. 3-Bromoquinoline was assessed for its possible mutagenic potential. For this purpose AMES test was performed  in Salmonella typhimurium strains TA 98 and TA 100. The test material was exposed at the concentration of 0, 6.7,10,33,67,100,333,667 and 1000 µg/plate in the presence and absence of S9. No mutagenic effects were observed. Only the data on TA100 with metabolic activation are reported here (Table) as the test substances tested on TA98 with and without S9 activation and on TA100without S9 activation were inactive. Therefore 3-Bromoquinoline was considered to be non mutagenic in presence and absence of S9.Hence the substance cannot be classified as gene mutant in vitro.

In a study for structurally and functionally similar read across chemical, Gene mutation toxicity study was performed by Minako Nagao et al. (Mutation Research, 1977) to determine the mutagenic nature 2 Chloroquinoline (612-62-4). The read across substances share high similarity in structure and log kow .Therefore, it is acceptable to derive information on mutation from the analogue substance. In vitro genetic toxicity study was performed to determine the mutagenic nature of 2 chloroquinoline. The study was performed using Salmonella typhimurium strains TA98 and TA100 in the absence and presence of exogenous metabolic activation system. The study was carried out by using Preincubation at 37oC for 20 min. The test chemical was dissolved in DMSO and exposed at a concentration of 0, 4 or 8 µmoles /plate. 2 Chloroquinoline did not induce gene mutation in Salmonella typhimurium strain TA98 and TA100 in the presence and absence of S9 metabolic activation system and hence it does not exhibit gene mutation ability in vitro.

In a study for structurally and functionally similar read across chemical, Gene mutation toxicity study was performed by Asim Kumar Debnath et al (Mutation Research, 1992) to determine the mutagenic nature of 6-Methylquinoline (91-62-3) using Salmonella typhimurium strains. The read across substances share high similarity in structure and log kow .Therefore, it is acceptable to derive information on mutation from the analogue substance. 6-Methylquinoline was assessed for its possible mutagenic potential. For this purpose AMES test was performed in Salmonella typhimurium strains TA 98 and TA 100. The test material was exposed at the concentration of 0, 3.3,10,33,100 and 333 µg/plate in the presence and absence of S9. No mutagenic effects were observed. Only the data on TA100 with metabolic activation are reported here (Table) as the test substances tested on TA98 with and without S9 activation and on TA100without S9 activation were inactive. Therefore 6-Methylquinoline was considered to be non mutagenic in presence and absence of S9.Hence the substance cannot be classified as gene mutant in vitro.

Based on the data available for the target chemical and applying weight of evidence 3-Bromoquinoline (5332-24-1)does not exhibit gene mutation in vitro. Hence the test chemical is not likely to classify as a gene mutant in vitro.

Justification for classification or non-classification

Thus based on the above annotation and CLP criteria for the target chemical . 3-Bromoquinoline (5332-24-1)does not exhibit gene mutation in vitro. Hence the test chemical is not likely to classify as a gene mutant in vitro.